ClinicalTrials.gg
RecruitingNCT06059495DEWIUpdated Aug 26, 2026

DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

A Phase 2 interventional study of Dostarlimab in Adenocarcinoma - GEJ and Gastric Adenocarcinoma, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group. Recruiting at 18 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group · Phase 2, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study aims to determine whether surgery can be safely avoided in patients achieving a complete response, defined by negative endoscopy and tumor-free biopsies after treatment.

Read the detailed description

Patients with localized, resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma are currently treated with radical surgery, the only curative option, typically combined with perioperative chemotherapy. However, surgery is associated with substantial morbidity and a significant impact on quality of life. Given the high efficacy of immune checkpoint inhibitors in localized dMMR/MSI-H tumors, surgery omission may be a potential strategy for selected patients.

This national, multicenter, open-label phase II study will evaluate dostarlimab in patients with localized dMMR/MSI-H gastric or GEJ adenocarcinoma. The primary objective is to determine whether a watch-and-wait approach can safely replace surgery in patients achieving a complete response after treatment, defined by negative endoscopy and tumor-free biopsies.

Study aims Main cohort: To evaluate dostarlimab followed by a watch-and-wait approach in patients with localized dMMR/MSI-H gastric or GEJ adenocarcinoma.

Additional unfit cohort (patients unfit for surgery): To evaluate the efficacy of dostarlimab in patients aged >70 years with localized dMMR/MSI-H gastric or GEJ adenocarcinoma who are deemed unfit for surgical resection.

Sample size Main initial cohort study (phase II): A total of 89 patients will be included (59 patients in the original protocol conducted in France and Italy, and an additional 30 patients to be enrolled exclusively in France).

Additional unfit cohort: A total of 39 patients will be included (20 patients in the original protocol conducted in France and Italy, and an additional 19 patients to be enrolled exclusively in France).

02

Conditions studied

  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma

Keywords

  • dMMR
  • MSI-H
  • dostarlimab
  • watch-and-wait
  • surgery
  • immunotherapy
03

In context

Lead sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group is the lead sponsor of 76 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion and exclusion criteria are identical in both cohorts, except for inclusion criteria 3 and 4.

Inclusion criteria

Inclusion criteria

The patient is eligible to be included in the study only if all the following criteria apply:

  1. Is capable of giving signed and dated ,
  2. Has an PS of 0-1,
  3. Age ≥18 years old:

    • A patient over 70 years of age is eligible to participate in the main initial cohort if the patient respects all the criteria and has a score G8 of ≥14.
    • A patient over 70 years with a score G8 \<14 should have a consultation with an onco-geriatrician to determine the best treatment or therapeutic strategy based on age and co-morbidity. After this consultation, the patient is eligible for main initial cohort if "fits for surgery" with no to repeated UGI endoscopy with (no change to the initial protocol) and can follow the study plan and procedures outlined in the study.
    • If a patient is over 70-year-old, has a G8 score \<14, and is unfit for surgery (as determined by onco-geriatric advice and multidisciplinary team [MDT] conclusion), the patient cannot be included in the phase II study (main initial cohort). This patient can be included in the unfit supplemental cohort, with the available Geriatric Core Dataset (G-CODE) test result being mandatory for inclusion (No switching between cohorts is allowed).
  4. Has proven non- gastric or OGJ adenocarcinoma cT2 to T4, Nx, M0 after computed tomography thorax-abdomen-pelvis (TAP-CT) and echo-endoscopy (EUS), performed within 6 weeks before inclusion, according to the 7th Edition of the International Union Against Cancer; NB1: Echo-endoscopy will be performed only if the tumor is not obstructive at UGI endoscopy ± a new UGI endoscopy with 10 biopsies, photos (if not done at the first UGI endoscopy done for diagnosis). If obstructive, the tumor will be classified as cT3 or cT4 (in the situation when the tumor was obstructive and prevented EUS, it was classified T3N+, if it did not invade the adjacent organs on CT scan, because obstructing tumors represented locally advanced disease in the vast majority of cases in previous studies). In this case a new UGI endoscopy must be done with 10 biopsies, photos (if not done at the first GGI endoscopy done for diagnosis).

    NB2: Echo endoscopy is not mandatory/performed for patient included in additional unfit cohort. TNM stage will be determine by CT scanner.

  5. Has no peritoneal carcinomatosis (optional coelioscopy; recommended in case of doubt/ suspicious on CT/ imaging),
  6. Has not received prior therapy (chemotherapy, radiotherapy, or immunotherapy) for localized gastric or OGJ adenocarcinoma,
  7. Tumor status confirmed to be dMMR/MSI-H as follows:

    - MMR protein expression status will be evaluated by immunohistochemistry (IHC) with four antibodies (anti-hMLH1, anti-hMSH2, anti-hMSH6, anti-hPMS2) according to the local procedures. dMMR will be defined as loss of MLSH1 and PMS2, loss of MSH2 and MSH6, or loss of only one protein with presence of MSI-H.

    MSI analysis will be performed by polymerase chain reaction [PCR] using a pentaplex panel (BAT-25, BAT-26, NR-21, NR-24, and NR-27; PROMEGA). MSI-H is defined as instability in two or more of the five studied markers. For this study, samples with 2 unstable markers will also undergo MMR analysis by IHC. Agreement of Sponsor (GERCOR) on a dMMR/MSI status is mandatory to include the patient (the patient's file [an anonymized mail] must be sent to Sponsor). Approval/refusal email for inclusion of the patient will be sent by the Sponsor within 24 hours of receipt of the Investigator email. In case of discrepancy between IHC and PCR, the final decision about the dMMR/MSI status will be taken by GERCOR or coordinating investigator,

  8. Has hematological status: (ANC) ≥1.5 x 109/L; ≥100 x 109/L; ≥9 g/dL,
  9. Has adequate renal function: serum creatinine level ≤150 µM and clearance ≥30 ml/min (Modification of the Diet in Renal Disease [] or Cockcroft and Gault),
  10. Has adequate liver function: ≤1.5 x (ULN) of direct ≤ ULN for participants with total bilirubin levels >1.5 x ULN (inclusion possible if known Gilbert syndrome), alkaline phosphatase \<5 x ULN, (ALT), and aspartate aminotransferase (AST) ≤2.5 x ULN,
  11. Has (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5 x ULN, except for the patient on anticoagulant therapy who must have PT-INR-aPTT within therapeutic range is deemed appropriate by the Investigator,
  12. Has radiological tumor assessment at screening performed within 6 weeks before inclusion according to version 1.1 by chest, abdomen, and pelvis CT, showing the absence of metastatic or non-surgical disease,
  13. A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    • Is a woman of non- as defined: i/ ≥ 45 years of age and has not had menses for >1 year, ii/ Amenorrheic for \<2 years without a hysterectomy and oophorectomy and have a follicle stimulating hormone (FSH) value in the range upon pre-study (screening) evaluation, iii/ post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, magnetic resonance imaging (MRI), or CT scan. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must fulfill the criteria in Inclusion criteria 15. Information must be captured appropriately within the site's source documents,
    • Has negative pregnancy blood test within 72 hours before the first dose of dostarlimab, AND
    • If woman of childbearing potential (WOCBP), female patient must be willing to use a highly effective form of from screening throughout the study treatment and 4 months after the last dose of dostarlimab,
  14. Male participants are eligible to participate if they agree to the following during the study treatment and for 4 months after the last dose of dostarlimab:

    • Refrain from donating sperm,
    • Must use contraception/barrier as follows:

      • Agree to use a male condom when having sexual intercourse with a WOCBP who is not currently pregnant.
      • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person,
  15. Provides primary tumor tissue samples (processed as formalin-fixed, paraffin-embedded [FFPE] blocks or freshly frozen) acquired during UGI endoscopy together with images (mandatory), NB: The patient's agreement will be specifically requested for endoscopic images in the patient information note and informed consent for their use as clinical data that may be analyzed and presented in publications. These data will be used in the same manner as other personal data. The confidentiality of these data will be maintained,
  16. Is willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study,
  17. Is registered in the National Health Care System (PUMa - Protection Universelle Maladie included).

Exclusion criteria

Exclusion criteria

The patient is ineligible for the study if any of the following criteria apply:

  1. Has received prior concomitant unplanned antitumor therapy (e.g., chemotherapy, molecular targeted therapy, immunotherapy),
  2. Has received treatment with any medicinal product within 28 days prior to study entry,
  3. Has a treatment anticoagulant or hemostasis disorder contraindicating - during endoscopy,
  4. Has had major surgical procedure within 28 days (4 weeks) prior to the first dose of study treatment,
  5. Has other serious and uncontrolled non-malignant disease (including active infection) or is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study,
  6. Has other concomitant or previous other than the disease under study, except as noted below:

    i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer from which the patients was in complete remission for ≥3 years,

  7. Has (M stage disease) whatever the location,
  8. Is pregnant or breastfeeding,
  9. Has (HIV),
  10. Has a documented surface antigen (HBsAg) positive result wither at the pre-inclusion visit or within 3 months prior to the first dose of the study intervention, along with and known active hepatitis, including acute or chronic hepatitis B virus (HBV).

    Exception: For patients who are HBsAg positive but do not have hepatitis (neither acute nor chronic HBV), antiviral treatment is recommended prior to treatment with dostarlimab:

    • if the HBV DNA level is ≥ 500 IU/mL or 2,500 copies/mL: antiviral treatment is recommended before starting dostarlimab and should be initiated within 3 weeks of starting immunotherapy or, at the latest, concomitantly. This treatment should continue for up to 12 months after the end of treatment with dostarlimab or any other therapy.
    • if the HBV DNA level is \< 500 IU/mL or 2,500 copies/mL: antiviral treatment is recommended before starting dostarlimab and should be initiated concurrently at the latest. This treatment should be continued for up to 12 months after the end of treatment with dostarlimab or any other immunosuppressive therapy.
  11. Has virus (HCV) prior to inclusion, Note: Patients positive for HCV antibody are eligible only if PCR testing is negative for HCV RNA.
  12. Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent,
  13. Impossibility of submitting to the medical follow-up of the study for geographical, social, or psychiatric illness.

    Non-eligible to immunotherapy:

  14. Has pyloric tumor, Note: tumors of the pylorus will be excluded because of the risk of high occlusion in case of pseudo progression and associated surgery,
  15. Has any history of disease including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, Note: History of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.

    Note: Controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.

  16. Has a history of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest imaging,
  17. Has received any live, attenuated vaccine within 14 days prior to the firs dose of study treatment or such administration is anticipated during the study,
  18. Has received prior therapy with any immune-, including antibodies or drugs targeting CD137, CTLA-4, PD-1, or PD-L1 or other checkpoint pathways,
  19. Has had prior bone marrow transplantation or prior solid organ transplantation,
  20. Has received treatment with systemic or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to the first dose of treatment or is required to receive systemic immunosuppressive medications during the study. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

Note: Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled into the study after approval of Medical Contact. Note: Subjects are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses including doses >10 mg daily prednisone is permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type reaction caused by a contact allergen) is permitted.

Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (estimated)

Study arms

  • Experimental
    Dostarlimab-based treatment

    After inclusion patients will receive dostarlimab at 500 mg q3w (± 2-3 days) for 4 cycles (C1-C4). Then, an adaptive treatment strategy will be determined based on clinical assessment of the patient.

    Drug: Dostarlimab

Interventions

  • Post-Inclusion: Dostarlimab 500mg IV q3wx4 cycles (Cs). Week 12 (W12) * cCR (both cohorts): Dostarlimab 1,000mg q6w×2 cycles. * Downstaging (Stage 2-3), no PD/mets: Dostarlimab 500mg q3w×4Cs. * Main cohort: SD/PD, Stage 1, positive(+), no cCR→Surgery. Post-surgery: Becker-TRG 1a/1b/2→Dostarlimab 1,000mg q6w×6Cs; Becker-TRG 3→Stop Trt. * Additional unfit cohort: SD/PD, Stage 1, biopsy(+) ± mets→Stop dostarlimab, withdraw from Trt, investigator-directed care, remain in FU. W24 * cCR at W12\&W24: Dostarlimab 1,000mg q6w×4Cs. * cCR at W12 but not W24: * Main cohort: Stop dostarlimab; surgery/adjuvant Trt per investigator. * Additional unfit cohort: Stop dostarlimab; withdraw from Trt; FU only. * Downstaging at W12 + cCR at W24: Dostarlimab 1,000mg q6w×4Cs. * Downstaging at W12 but no cCR at W24: * Main cohort: Surgery; if Becker-TRG 1a/1b/2, dostarlimab 1,000mg q6w×4Cs. * Additional unfit cohort: Stop dostarlimab, withdraw from Trt, investigator-directed care, remain in FU.

    Also known as: Jemperli

06

What researchers measure

Primary outcomes

  1. Clinical complete response (cCR)

    Main initial cohort: To evaluate clinical complete response (cCR) at 1 year defined as the rate of patients who at 1 year from the start of therapy with dostarlimab are alive, were not operated for tumor resection, are free of disease progression (locoregional or metastases), have all negative biopsies, and show endoscopy downstaging stage 3 or 4 (endoscopic grade). Additional unfit cohort: To evaluate cCR at 1 year defined as the rate of patients who at 1 year from the start of therapy with dostarlimab are alive, are free of disease progression (locoregional or metastases), have all negative biopsies, and show endoscopy downstaging stage 3 or 4 (endoscopic grade).

    Time frame: At 1 year from the start of treatment with dostarlimab.

Secondary outcomes

  1. Pathological complete response (pCR)

    Pathological complete response is defined as 100% fibrosis or fibro-inflammation or necrosis or granulomatous reaction within an entire gross lesion without microscopic evidence of carcinoma, and no positive lymph nodes, after examination of the complete macroscopic surgical specimen equivalent to a Becker TRG Grade 1a (complete regression).

    Time frame: up to 5 years

  2. Loco/loco-regional and distant recurrence

    Loco/loco-regional recurrence is defined as cancer recurrence within the regional resection area or local anastomotic site. Distant recurrence is defined as peritoneal recurrence, liver metastasis or metastasis at other extra-abdominal sites as well as nodal metastasis beyond the regional nodes

    Time frame: up to 5 years

  3. Event-free survival (EFS)

    Event-free survival is defined as time from first dose of treatment to surgery for tumoral resection, first progression of disease local or distant recurrence, or death due to any cause. Alive patients without event will be censored at the last follow-up.

    Time frame: up to 5 years

  4. Time to treatment failure (TTF)

    Time to treatment failure is defined as the interval between initiating therapy (first dose of dostarlimab) and the earliest of clinical progression, depending on whether the patient had surgery for tumoral resection or not, or death. Measured in both cohorts.

    Time frame: up to 5 years

  5. Disease-free survival (DFS)

    Disease-free survival is defined only for patient with surgery (partial or complete gastrectomy or oesogastrectomy) as the time between the date of surgery and the date either of recurrence or death from any cause.

    Time frame: up to 5 years

  6. Overall survival (OS)

    Overall survival is defined as the time between the date of the first dose of study treatment and the death date. Measured in both cohorts.

    Time frame: up to 5 years

  7. The number of patients who did not undergo surgery for tumor resection without distant metastases

    The number of patients who did not undergo surgery for tumor resection without distant metastases at 12 and 24 months,

    Time frame: up to 5 years

  8. The number of patients who did not undergo surgery for tumor resection with distant metastases

    The number of patients who did not undergo surgery for tumor resection with distant metastases at 12 and 24 months,

    Time frame: up to 5 years

  9. Progression-free survival (PFS) in additional cohort

    Progression-free survival is defined as time from first dose of treatment to first progression of disease local or distant recurrence, or death due to any cause. Alive patients without event will be censored at the last follow-up.

    Time frame: up to 5 years

  10. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) following dostarlimab treatment

    Patients will be assessed for AEs and SAEs throughout the study using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Measured in both cohorts.

    Time frame: up to 5 years; from the date of dostarlimab initiation to the date of death

  11. Health-related quality of life (HRQoL) by the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30)

    HRQoL assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 generates scores transformed to a 0 to 100 scale. For the Global Health Status/Quality of Life scale and functional scales, higher scores indicate better HRQoL and functioning. For symptom scales/items, higher scores indicate greater symptom burden and worse quality of life. Measured in both cohorts.

    Time frame: up to 5 years

  12. Health-related quality of life (HRQoL) by the EORTC oesophago-gastric (EORTC QLQ-OG25) questionnaire

    HRQoL assessed using the European Organisation for Research and Treatment of Cancer Oesophago-Gastric Cancer Questionnaire (EORTC QLQ-OG25). The EORTC QLQ-OG25 consists of symptom scales and single-item measures that are transformed to scores ranging from 0 to 100. Higher scores indicate greater symptom burden, more problems, and worse health-related quality of life. Measured in both cohorts.

    Time frame: up to 5 years

  13. Number of days spent in the hospital (DIH)

    Number of days spent in the hospital (DIH) measured in additional unfit cohort.

    Time frame: up to 5 years

  14. Morbidity in case of surgery

    Morbidity in case of surgery (complication or death occurring within 90 postoperative days according to the Clavien Dindo's classification) measured in main cohort only.

    Time frame: up to 5 years

07

Study locations

17 of 18 sites recruiting
  • Besancon University Hospital Center
    Besançon, France
    Recruiting
    • Christophe BORG, Prof · Contact
  • Centre Hospitalier Universitaire De Bordeaux
    Bordeaux, France
    Recruiting
    • Denis SMITH, MD · Contact
  • Centre Hospitalier Regional Et Universitaire De Brest
    Brest, France
    Recruiting
    • Jean-Philippe Jean-Philippe METGES, MD · Contact
  • Henri Mondor Hospital
    Créteil, France
    Recruiting
    • Christophe TOURNIGAND, Prof, MD · Contact
  • CHRU Lille
    Lille, France
    Recruiting
    • Guillaume PIESSEN, MD · Contact
    • Guillaume PIESSEN, MD · Principal investigator
  • Centre Leon Berard
    Lyon, France
    Recruiting
    • Clélia COUTZAC, MD · Contact
  • Institut Paoli Calmettes
    Marseille, France
    Recruiting
    • Christelle DE LA FOUCHARDIERE, Prof, MD · Contact
  • Institut régional du Cancer de Montpellier - ICM Val d'Aurelle Oncologie Médicale
    Montpellier, France
    Recruiting
    • Antoine ADENIS, Prof, MD · Contact
  • Institut Mutualiste Montsouris
    Paris, France
    Recruiting
    • Emilie SOULARUE, MD · Contact
  • Saint Antoine Hospital
    Paris, France
    Recruiting
    • Thierry ANDRE, Prof, MD · Contact
    • Thierry ANDRE, MD · Principal investigator
  • Centre Hospitalier Universitaire De Poitiers
    Poitiers, France
    Recruiting
    • David TOUGERON, Prof, MD · Contact
  • Centre Hospitalier Universitaire Reims
    Reims, France
    Recruiting
    • Olivier BOUCHE, Prof, MD · Contact
  • Centre Hospitalier De Saint Malo
    St-Malo, France
    Not yet recruiting
    • Romain DESGRIPPES, MD · Contact
  • Fondazione. IRCCS Istituto Nazionale dei Tumori di Milano
    Milan, Italy
    Recruiting
    • Alessandra RAIMONDI, MD · Contact
  • Fondazione I.R.C.C.S. Istituto Oncologico Veneto
    Padova, Italy
    Recruiting
    • Sabina MURGIONI, MD · Contact
  • Azienda USL della Romagna OSPEDALE DI RAVENNA
    Ravenna, Italy
    Recruiting
    • Stefano TAMBERI, MD · Contact
  • Istituto Clinico Humanitas
    Rozzano, Italy
    Recruiting
    • Alberto PUCCINI, MD · Contact
  • Azienda Sanitaria Universitaria friuli Centrale Presidio Ospedaliero Santa Maria della Misericordia di Udine
    Udine, Italy
    Recruiting
    • Silvo Ken GARATTINI, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Sep 2028, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Sep 28, 2023
StartActual
Jan 22, 2024
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059495
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Jan 22, 2024
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Aug 26, 2026

Study contacts

Marie-Line GARCIA LARNICOL, MD
Contact
gercor@gercor.com.fr
+33 (01) 40 20 85 00
Thierry Andre, MD
principal investigator · Saint-Antoine Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion